Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing.

Gerhart SV, Kellner WA, Thompson C, Pappalardi MB, Zhang XP, Montes de Oca R, Penebre E, Duncan K, Boriack-Sjodin A, Le B, Majer C, McCabe MT, Carpenter C, Johnson N, Kruger RG, Barbash O.

Sci Rep. 2018 Jun 26;8(1):9711. doi: 10.1038/s41598-018-28002-y.

2.

MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers.

Wyce A, Matteo JJ, Foley SW, Felitsky DJ, Rajapurkar SR, Zhang XP, Musso MC, Korenchuk S, Karpinich NO, Keenan KM, Stern M, Mathew LK, McHugh CF, McCabe MT, Tummino PJ, Kruger RG, Carpenter C, Barbash O.

Oncogenesis. 2018 Apr 20;7(4):35. doi: 10.1038/s41389-018-0043-9.

3.

PRMT5 Is a Critical Regulator of Breast Cancer Stem Cell Function via Histone Methylation and FOXP1 Expression.

Chiang K, Zielinska AE, Shaaban AM, Sanchez-Bailon MP, Jarrold J, Clarke TL, Zhang J, Francis A, Jones LJ, Smith S, Barbash O, Guccione E, Farnie G, Smalley MJ, Davies CC.

Cell Rep. 2017 Dec 19;21(12):3498-3513. doi: 10.1016/j.celrep.2017.11.096.

4.

Targeting Histone Methylation in Cancer.

McCabe MT, Mohammad HP, Barbash O, Kruger RG.

Cancer J. 2017 Sep/Oct;23(5):292-301. doi: 10.1097/PPO.0000000000000283. Review.

PMID:
28926430
5.

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.

Chan-Penebre E, Kuplast KG, Majer CR, Boriack-Sjodin PA, Wigle TJ, Johnston LD, Rioux N, Munchhof MJ, Jin L, Jacques SL, West KA, Lingaraj T, Stickland K, Ribich SA, Raimondi A, Scott MP, Waters NJ, Pollock RM, Smith JJ, Barbash O, Pappalardi M, Ho TF, Nurse K, Oza KP, Gallagher KT, Kruger R, Moyer MP, Copeland RA, Chesworth R, Duncan KW.

Nat Chem Biol. 2015 Jun;11(6):432-7. doi: 10.1038/nchembio.1810. Epub 2015 Apr 27.

PMID:
25915199
6.

SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.

Mazur PK, Reynoird N, Khatri P, Jansen PW, Wilkinson AW, Liu S, Barbash O, Van Aller GS, Huddleston M, Dhanak D, Tummino PJ, Kruger RG, Garcia BA, Butte AJ, Vermeulen M, Sage J, Gozani O.

Nature. 2014 Jun 12;510(7504):283-7. doi: 10.1038/nature13320. Epub 2014 May 21.

7.

Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762.

Chaidos A, Caputo V, Gouvedenou K, Liu B, Marigo I, Chaudhry MS, Rotolo A, Tough DF, Smithers NN, Bassil AK, Chapman TD, Harker NR, Barbash O, Tummino P, Al-Mahdi N, Haynes AC, Cutler L, Le B, Rahemtulla A, Roberts I, Kleijnen M, Witherington JJ, Parr NJ, Prinjha RK, Karadimitris A.

Blood. 2014 Jan 30;123(5):697-705. doi: 10.1182/blood-2013-01-478420. Epub 2013 Dec 13.

8.

Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer.

Wyce A, Degenhardt Y, Bai Y, Le B, Korenchuk S, Crouthame MC, McHugh CF, Vessella R, Creasy CL, Tummino PJ, Barbash O.

Oncotarget. 2013 Dec;4(12):2419-29.

9.

The FBXO4 tumor suppressor functions as a barrier to BRAFV600E-dependent metastatic melanoma.

Lee EK, Lian Z, D'Andrea K, Letrero R, Sheng W, Liu S, Diehl JN, Pytel D, Barbash O, Schuchter L, Amaravaradi R, Xu X, Herlyn M, Nathanson KL, Diehl JA.

Mol Cell Biol. 2013 Nov;33(22):4422-33. doi: 10.1128/MCB.00706-13. Epub 2013 Sep 9.

10.

BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models.

Wyce A, Ganji G, Smitheman KN, Chung CW, Korenchuk S, Bai Y, Barbash O, Le B, Craggs PD, McCabe MT, Kennedy-Wilson KM, Sanchez LV, Gosmini RL, Parr N, McHugh CF, Dhanak D, Prinjha RK, Auger KR, Tummino PJ.

PLoS One. 2013 Aug 23;8(8):e72967. doi: 10.1371/journal.pone.0072967. eCollection 2013.

11.

[DNA methylation profiling of the vascular tissues in the setting of atherosclerosis].

Nazarenko MS, Markov AV, Lebedev IN, Sleptsov AA, Frolov AV, Barbash OL, Puzyrev VP.

Mol Biol (Mosk). 2013 May-Jun;47(3):398-404. Russian.

12.

Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation.

Van Aller GS, Reynoird N, Barbash O, Huddleston M, Liu S, Zmoos AF, McDevitt P, Sinnamon R, Le B, Mas G, Annan R, Sage J, Garcia BA, Tummino PJ, Gozani O, Kruger RG.

Epigenetics. 2012 Apr;7(4):340-3. doi: 10.4161/epi.19506. Epub 2012 Apr 1.

13.

The Fbx4 tumor suppressor regulates cyclin D1 accumulation and prevents neoplastic transformation.

Vaites LP, Lee EK, Lian Z, Barbash O, Roy D, Wasik M, Klein-Szanto AJ, Rustgi AK, Diehl JA.

Mol Cell Biol. 2011 Nov;31(22):4513-23. doi: 10.1128/MCB.05733-11. Epub 2011 Sep 12.

14.

Phosphorylation-dependent regulation of SCF(Fbx4) dimerization and activity involves a novel component, 14-3-3ɛ.

Barbash O, Lee EK, Diehl JA.

Oncogene. 2011 Apr 28;30(17):1995-2002. doi: 10.1038/onc.2010.584. Epub 2011 Jan 17.

15.

Lysine 269 is essential for cyclin D1 ubiquitylation by the SCF(Fbx4/alphaB-crystallin) ligase and subsequent proteasome-dependent degradation.

Barbash O, Egan E, Pontano LL, Kosak J, Diehl JA.

Oncogene. 2009 Dec 10;28(49):4317-25. doi: 10.1038/onc.2009.287.

16.

SCF(Fbx4/alphaB-crystallin) E3 ligase: when one is not enough.

Barbash O, Diehl JA.

Cell Cycle. 2008 Oct;7(19):2983-6. Epub 2008 Oct 12. Review.

PMID:
18818515
17.

Genotoxic stress-induced cyclin D1 phosphorylation and proteolysis are required for genomic stability.

Pontano LL, Aggarwal P, Barbash O, Brown EJ, Bassing CH, Diehl JA.

Mol Cell Biol. 2008 Dec;28(23):7245-58. doi: 10.1128/MCB.01085-08. Epub 2008 Sep 22.

18.

Mutations in Fbx4 inhibit dimerization of the SCF(Fbx4) ligase and contribute to cyclin D1 overexpression in human cancer.

Barbash O, Zamfirova P, Lin DI, Chen X, Yang K, Nakagawa H, Lu F, Rustgi AK, Diehl JA.

Cancer Cell. 2008 Jul 8;14(1):68-78. doi: 10.1016/j.ccr.2008.05.017.

19.
20.

Phosphorylation-dependent ubiquitination of cyclin D1 by the SCF(FBX4-alphaB crystallin) complex.

Lin DI, Barbash O, Kumar KG, Weber JD, Harper JW, Klein-Szanto AJ, Rustgi A, Fuchs SY, Diehl JA.

Mol Cell. 2006 Nov 3;24(3):355-66.

21.

Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1.

Benzeno S, Lu F, Guo M, Barbash O, Zhang F, Herman JG, Klein PS, Rustgi A, Diehl JA.

Oncogene. 2006 Oct 12;25(47):6291-303. Epub 2006 May 29.

PMID:
16732330
22.

The oxidative stressor arsenite activates vascular endothelial growth factor mRNA transcription by an ATF4-dependent mechanism.

Roybal CN, Hunsaker LA, Barbash O, Vander Jagt DL, Abcouwer SF.

J Biol Chem. 2005 May 27;280(21):20331-9. Epub 2005 Mar 23.

Supplemental Content

Loading ...
Support Center